Status:
UNKNOWN
Prevention of Decompensation in Liver Cirrhosis
Lead Sponsor:
Odense University Hospital
Collaborating Sponsors:
Lundbeck Foundation
University of Southern Denmark
Conditions:
Alcoholic Liver Cirrhosis
Ascites
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine whether losartan, an angiotensin II blocker prevents the sodium retention in patients with liver cirrhosis and by that reduces the fluid retention. Moreover i...
Detailed Description
Patients with cirrhosis tend to retain sodium and water leading to the development of ascites, which in the terminal stage of decompensation cannot be eliminated despite the use of massive diuretic tr...
Eligibility Criteria
Inclusion
- The presence of cirrhosis in a liver biopsy; or, in the absence of histology, clinical and laboratory evidence of cirrhosis combined with years of excessive alcohol intake.
- Age 18-70 years
Exclusion
- Cirrhosis due to alpha1-antitrypsin deficiency, viral hepatitis or autoimmunity.
- Renal disease evidenced by proteinuria \> 0,5 g/day.
- Heart disease
- Hypertension
- Cancer or disease other than cirrhosis expected to limit life expectancy to \< 5 years.
- Pregnancy or lactation
- Sepsis within 5 days
- Gastrointestinal bleeding within 5 days
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2011
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00239096
Start Date
September 1 2005
End Date
September 1 2011
Last Update
October 14 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Odense University Hospital
Odense, Odense, Denmark, 5000